Dementia, a progressive disorder that impacts memory and independence, affects millions globally. While many are aware of ...

Anavex Life Sciences shares were up 7% to $11.25 after the company said it saw positive trial results for its oral blarcamesine for the treatment of early Alzheimer's disease. The clinical-stage ...

Alzheimer's disease (AD) is a devastating neurological disorder that affects more than 37 million people worldwide 1. The economic burden of AD is massive; in the United States alone, the ...

Mounting evidence suggests that non-steroidal anti-inflammatory drugs may be useful in reducing the risk of Alzheimer disease. After much study, the mechanism by which these drugs reduce the ...

Discover how dopamine’s unexpected role in breaking down harmful plaques could revolutionize Alzheimer's treatment and ...

NDAQ:AVXL) Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of ...

The doctor said his pulse rate is low, and the medications have a tendency to lower the pulse even more, which can be dangerous. His Alzheimer's stage is 4-5, and his MMSE score was 5 out of 30. Is ...

"In people with progressive cognitive decline, the diagnosis of Alzheimer's disease requires a demonstration of amyloid and ...